Read the latest news and views from Lymphoma Action.
Use the drop down filter to find the most relevant news for you.
On Saturday 12 June, we will be celebrating 35 years of supporting people affected by lymphoma. Our Chief Executive, Ropinder Gill, has recorded a special message to mark the occasion, and to thank all of our wonderful supporters.
Mogamulizumab has been approved for people with rare types of relapsed or refractory skin lymphoma, and acalabrutinib has been approved as a first-line treatment for some people with chronic lymphocytic leukaemia (CLL).
This week is Carers week, an annual campaign to raise awareness of caring and to recognise the contribution of carers across the UK. At Lymphoma Action, we have a host of resources available to support people who may be caring for someone affected by lymphoma.
We were delighted to have the opportunity to talk with Anna, whose parents, Tim and Felicity Hilder were instrumental in starting the charity over 35 years ago. Here, she explains why Lymphoma Action is still close to her heart as we celebrate 35 years of supporting people affected by lymphoma.
The results of the LOTIS-2 trial of loncastuximab tesirine for people with difficult-to-treat large B-cell lymphomas are encouraging.
We are pleased to welcome Shaf Mansour as a Trustee of Lymphoma Action.
For good health and wellbeing, you can’t separate physical and mental health.
Chlormethine gel is now available on the NHS in Scotland for adults with mycosis fungoides.
New guidelines give clear treatment recommendations for people with PTLD.
Sun safety is important as some treatments for lymphoma can make skin more sensitive to sunlight.
